How does 0DPB's PE Ratio compare to its peers?

0DPB is good value based on its Price-To-Earnings Ratio (13x) compared to the peer average (83.8x).

How does 0DPB's PE Ratio compare vs other companies in the European Biotechs Industry?

0DPB is good value based on its Price-To-Earnings Ratio (13x) compared to the European Biotechs industry average (26.8x).

What is 0DPB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0DPB is good value based on its Price-To-Earnings Ratio (13x) compared to the estimated Fair Price-To-Earnings Ratio (19.6x).

What is the Fair Price of 0DPB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

0DPB (DKK184.6) is trading below our estimate of [[fair value]] (DKK1170.66)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Bavarian Nordic (LSE:0DPB) - Stock Price, News & Analysis

0DPB Stock Overview

Develops, manufactures, and commercializes life-saving vaccines. More details

0DPB fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	0/6
Past Performance	5/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 84.2% below our estimate of its fair value

Earnings are forecast to grow 5.31% per year

Earnings grew by 54.6% over the past year

Trading at good value compared to peers and industry

Risk Analysis

Significant insider selling over the past 3 months

Bavarian Nordic A/S Competitors

Genus

LSE:GNS

UK£1.1b

Bioventix

AIM:BVXP

UK£199.7m

Ergomed

AIM:ERGO

UK£701.1m

MannKind

NasdaqGM:MNKD

US$1.9b

Price History & Performance

Summary of all time highs, changes and price drops for Bavarian Nordic
Historical stock prices
Current Share Price	DKK 171.30
52 Week High	DKK 295.40
52 Week Low	DKK 143.50
Beta	1.58
11 Month Change	-22.21%
3 Month Change	-37.05%
1 Year Change	12.07%
33 Year Change	-43.83%
5 Year Change	3.60%
Change since IPO	-47.48%

Recent updates

Shareholder Returns

	0DPB	GB Biotechs	GB Market
7D	-18.1%	-2.9%	-0.4%
1Y	12.1%	-21.1%	5.6%

Return vs Industry: 0DPB exceeded the UK Biotechs industry which returned -21.1% over the past year.

Return vs Market: 0DPB exceeded the UK Market which returned 5.6% over the past year.

Price Volatility

Is 0DPB's price volatile compared to industry and market?
0DPB volatility
0DPB Average Weekly Movement	6.8%
Biotechs Industry Average Movement	9.9%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	10.2%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: 0DPB has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: 0DPB's weekly volatility (7%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1992	1,609	Paul Chaplin	www.bavarian-nordic.com

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2.

Bavarian Nordic A/S Fundamentals Summary

How do Bavarian Nordic's earnings and revenue compare to its market cap?
0DPB fundamental statistics
Market cap	DKK 13.28b
Earnings (TTM)	DKK 1.12b
Revenue (TTM)	DKK 6.07b

11.9x

P/E Ratio

2.2x

P/S Ratio

Is 0DPB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0DPB income statement (TTM)
Revenue	DKK 6.07b
Cost of Revenue	DKK 2.33b
Gross Profit	DKK 3.74b
Other Expenses	DKK 2.62b
Earnings	DKK 1.12b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Mar 05, 2025

Earnings per share (EPS)	14.24
Gross Margin	61.57%
Net Profit Margin	18.43%
Debt/Equity Ratio	0.1%

How did 0DPB perform over the long term?

See historical performance and comparison

0DPB Stock Overview

Rewards

Risk Analysis

Bavarian Nordic A/S Competitors

LSE:GNS

UK£1.1b

AIM:BVXP

UK£199.7m

AIM:ERGO

UK£701.1m

NasdaqGM:MNKD

US$1.9b

Price History & Performance

Recent News & Updates

Third quarter 2024 earnings released: EPS: kr.0.90 (vs kr.4.40 loss in 3Q 2023)

Investor sentiment deteriorates as stock falls 17%

First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic's Mpox Vaccine

Bavarian Nordic A/S Upgrades Earnings Guidance for the Year 2024

Bavarian Nordic A/S Receives EMA Approval of Mpox Vaccine for Adolescents

Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine

Recent updates

Third quarter 2024 earnings released: EPS: kr.0.90 (vs kr.4.40 loss in 3Q 2023)

Investor sentiment deteriorates as stock falls 17%

First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic's Mpox Vaccine

Bavarian Nordic A/S Upgrades Earnings Guidance for the Year 2024

Bavarian Nordic A/S Receives EMA Approval of Mpox Vaccine for Adolescents

Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine

CEO & President recently sold kr.24m worth of stock

Bavarian Nordic A/S Announces First Doses of its Mpox Vaccine, Mva-BN

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Singapore

Second quarter 2024 earnings released

Bavarian Nordic A/S, Annual General Meeting, Apr 09, 2025

Bavarian Nordic A/S to Report Fiscal Year 2024 Results on Mar 05, 2025

Bavarian Nordic A/S Submits Data to EMA to Extend Mpox/Smallpox Vaccine Approval to Adolescents

New minor risk - Share price stability

Investor sentiment improves as stock rises 19%

Bavarian Nordic A/S Receives Positive Chmp Opinion for Including Mpox Real-World Effectiveness Data in European Marketing Authorization for Smallpox and Mpox Vaccine

Bavarian Nordic A/S Receives EMA Filing Acceptance and Validation of the MAA for Its Chikungunya Vaccine

Investor sentiment improves as stock rises 17%

Bavarian Nordic A/S Submits Marketing Authorization Application for Its Chikungunya Vaccine Candidate to Ema

Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer

First quarter 2024 earnings released: kr.1.50 loss per share (vs kr.5.10 profit in 1Q 2023)

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

New minor risk - Earnings quality

New major risk - Revenue and earnings growth

Full year 2023 earnings released: EPS: kr.19.20 (vs kr.4.93 loss in FY 2022)

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: kr.4.40 loss per share (vs kr.0.20 profit in 3Q 2022)

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk

Investor sentiment improves as stock rises 16%

Bavarian Nordic A/S Reports Additional Phase 3 Results and Provides Update on Development Program for its cVLP-Based COVID-19 Booster Vaccine Candidate, ABNCoV2

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 26%

Bavarian Nordic A/S Provides Update on RSV Vaccine Program

Bavarian Nordic A/S Reports Data from A Phase 3 Clinical Trial of Its Vlp-Based Chikungunya Virus Vaccine in Adults >=65 Years of Age Study Successfully Met Its Primary Endpoints

Bavarian Nordic A/S Reports 12-Month Durability Data from Phase 2 Clinical Trial of Covid-19 Vaccine Candidate

Bavarian Nordic A/S acquired Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $384 million.

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released: kr.4.90 loss per share (vs kr.7.37 loss in FY 2021)

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S Provides Earnings Guidance for Fiscal Year 2023

Bavarian Nordic A/S Provides Revenue Guidance for Fiscal Year 2022

Now 21% undervalued

Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults

Chairman recently sold kr.508k worth of stock

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: kr.0.20 (vs kr.1.30 loss in 3Q 2021)

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic A/S Announces Covid-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial

Bavarian Nordic A/S Appoints Luc Debruyne as Board of Directors

Bavarian Nordic A/S Revises Earnings Guidance for the Full Year 2022

Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine Candidate